Company Performance Metrics
Ray Holloway: CEO
TregTherapeutics is a preclinical stage company focused on the treatment and possible cure of multiple sclerosis.
The T lymphocyte is a key component in the acquired immune system, and a subset of T cells, the T-regulator cell (known as the Treg), plays an instrumental role in the control and regulation of the immune response. Named in recognition
of the vital functions this cell executes, TregTherapeutics Inc. is focused on developing a tolerogenic vaccine for the treatment and possible cure of multiple sclerosis. The corporation is a North Carolina-based preclinical-stage company whose proprietary technology is based upon an exclusive license granted by East Carolina University. The technology is a transformative platform that utilizes a novel vaccine approach that harnesses the power of Tregs to dramatically alter patient outcomes in response to autoimmune disease.
